To avoid becoming deal bait, Mylan CEO may have to make another big buy
It's been less than a week since Mylan completed its deal with Abbott, scooping up a large chunk of the Illinois company's overseas generics business. But CEO Heather Bresch is already hinting at another big transaction.
Sun Pharma buys GSK's Tasmania opiates business to expand pain offerings
India's top drugmaker, Sun Pharmaceutical Industries, has agreed to buy GlaxoSmithKline's opiates business in Australia, placing it as one of three owners that control the crop and production in Tasmania that is the world's largest legal supplier of pharmaceutical-grade opiates for painkillers.
Israeli device seed firm Rainbow Medical raises $25M from Chinese investors
Rainbow Medical will open an office in Shanghai to help facilitate strategic deals as part of a $25 million cash infusion from investors in China. The firm is an Israeli-based seed investor and incubator specifically for medical device and medical technology startups.
Diabetes devices drag down Abbott in Q4, but 2015 growth expected on FreeStyle Libre in EU
Abbott Laboratories' sales of medical devices slipped by 3.9% to $1.4 billion in the fourth quarter of 2014 over the same period a year earlier. The company is looking to gain traction in medical devices with its entrance into the electrophysiology market with the December completion of its Topera acquisition.
Abbott Labs continues Dx winning streak with bladder cancer biomarker deal
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.
Justice Department sues Omnicare for rigging kickbacks with Abbott
Once again, long-term care pharmacy Omnicare is at the center of a Department of Justice kickback probe. This time, the drugmaker in focus is Abbott Laboratories. The drug, Depakote.
Abbott snags CE mark for molecular diagnostic platform for sepsis
Abbott Laboratories snagged a CE mark for its molecular diagnostic platform for blood-related infections, continuing its diagnostics winning streak and moving the company one step closer to securing stateside approval for its product.
What's in a Big Pharma name? Abbott aims to find out with international branding push
Abbott Laboratories is hitching its wagon to growth in emerging markets, rolling out an expanded branding campaign to cozy up with consumers and amp up its presence abroad.
Smith & Nephew CEO to stay, not making move to Sanofi
Rumors have been circulating in recent weeks that the French CEO of Smith & Nephew, Olivier Bohuon, would jump ship to run Paris-based Sanofi. But Bohuon told employees at a town hall meeting that he is "very happy" at Smith & Nephew, and several people with knowledge of the matter said he isn't planning to leave.
Fresenius expansion plans in Russia sidelined by political turmoil
Planning to expand its production capacity in Russia and the former Soviet Republic, Germany's Fresenius Kabi agreed this year to partner up with Binnopharm, a Moscow-based drugmaker that has two manufacturing facilities making IV drugs, infusion solutions and active pharmaceutical ingredients, not unlike Fresenius. But the political situation in Russia has made that too difficult, so Fresenius and Binnopharm are exploring other ways to work together.